CARRIER COMPOSITION FOR NUCLEIC ACID TRANSPORT

(19)

(11)

EP 1 946 761 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	22.05.2013 Bulletin 2013/21

(45)	Mention of the grant of the patent:
	03.04.2013 Bulletin 2013/14

(21)	Application number: 06811872.8

(22)	Date of filing: 17.10.2006

(51)

International Patent Classification (IPC):

A61K 31/7105^(2006.01)
A61K 47/28^(2006.01)
A61K 47/48^(2006.01)
A61K 9/127^(2006.01)

A61K 47/18^(2006.01)
A61K 47/44^(2006.01)
A61K 48/00^(2006.01)
C12N 15/88^(2006.01)

(86)	International application number:
	PCT/JP2006/320617

(87)	International publication number:
	WO 2007/046356 (26.04.2007 Gazette 2007/17)

(54)	CARRIER COMPOSITION FOR NUCLEIC ACID TRANSPORT TRÄGERZUSAMMENSETZUNG FÜR DEN NUKLEINSÄURETRANSPORT COMPOSITION VECTRICE POUR LE TRANSPORT D'UN ACIDE NUCLEIQUE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30)

Priority:

18.10.2005 JP 2005303497

(43)	Date of publication of application:
	23.07.2008 Bulletin 2008/30

(73)	Proprietor: Otsuka Pharmaceutical Co., Ltd.
	Tokyo 101-8535 (JP)

(72)	Inventors:
	TOYOBUKU, Hidekazu Tokushima-shi Tokushima 771-0182 (JP) MIYAO, Hideo Tokushima-shi Tokushima 771-0182 (JP) SATO, Masako Tokushima-shi Tokushima 771-0192 (JP) SEKIGUCHI, Kazuo Otsu-shi Shiga 520-0106 (JP)

(74)	Representative: HOFFMANN EITLE
	Patent- und Rechtsanwälte Arabellastrasse 4 81925 München 81925 München (DE)

(56)

References cited: :

WO-A1-00/27795
WO-A1-2004/004758
US-A- 5 965 542

WO-A1-99/31132
WO-A2-2004/033620

ZEMLINSKA BARBARA ET AL: "Various cationic carriers for in vitro transfection of tumor and endothelial cell lines.", ACTA BIOCHIMICA POLONICA 2002 LNKD- PUBMED:12136952, vol. 49, no. 1, 2002, pages 285-290, XP002665623, ISSN: 0001-527X
SONG Y K ET AL: "Free liposomes enhance the transfection activity of DNA/lipid complexes in vivo by intravenous administration.", BIOCHIMICA ET BIOPHYSICA ACTA 24 JUN 1998 LNKD- PUBMED:9651508, vol. 1372, no. 1, 24 June 1998 (1998-06-24), pages 141-150, XP002665624, ISSN: 0006-3002
TSENG W.-C. ET AL.: 'Liposome-based gene therapy' PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY vol. 1, no. 5, 1998, pages 206 - 213, XP003012138
FARHOOD H. ET AL.: 'The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer' BIOCHIM. BIOPHYS. ACTA vol. 1235, no. 2, 04 May 1995, pages 289 - 295, XP000573182
ESPOSITO C. ET AL.: 'The analysis of serum effects on structure, size and toxicity of DDAB-DOPE and DC-Chol-DOPE lipoplexes contributes to explain their different transfection efficiency' COLLOIDS SURF B BIOINTERFACES vol. 53, no. 2, 01 December 2006, pages 187 - 192, XP005779262

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).